Details for Patent: 9,504,685
✉ Email this page to a colleague
Title: | Method for treating a pulmonary hypertension condition |
Abstract: | A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years. |
Inventor(s): | Gerber; Michael J. (Oakland, CA), Dufton; Christopher (Nederland, CO) |
Assignee: | Gilead Sciences, Inc. (Foster City, CA) |
Filing Date: | Apr 24, 2015 |
Application Number: | 14/695,775 |
Claims: | 1. A method for treating a human patient exhibiting a pulmonary arterial hypertension (PAH) of WHO Functional Class IV at baseline, comprising administering to the patient a therapeutically effective amount of ambrisentan. 2. The method of claim 1, wherein the PAH is further associated with a connective tissue disease (CTD). 3. The method of claim 1, wherein the ambrisentan is administered in a daily dosage amount of about 1 mg to about 25 mg. 4. The method of claim 3, wherein the ambrisentan is administered in a daily dosage amount of about 2.5 mg to about 10 mg. 5. The method of claim 4, wherein the administration continues for 12 weeks. 6. The method of claim 1, wherein the administration is initiated within 2 years following diagnosis of the PAH condition. |